DISCOUNT ZERTIFIKAT - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 07:20:28 2024-06-10 EDT | ||
| 114.1 EUR | +0.54% |
|
| Current month | +0.84% | ||
| 1 month | +2.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 114.1 | +0.54% |
| 24-06-07 | 113.5 | +0.20% |
| 24-06-06 | 113.2 | +0.03% |
| 24-06-05 | 113.2 | +0.12% |
| 24-06-04 | 113.1 | +0.07% |
Real-time Boerse Frankfurt Warrants
Last update June 10, 2024 at 07:20 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VYW |
| ISIN | DE000PC3VYW2 |
| Date issued | 2024-01-25 |
| Maturity | 2024-12-20 (193 Days) |
| Parity | 1 : 1 |
| Emission price | 105.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 114.1 € |
|---|---|
| Lowest since issue | 102.5 € |
| Spread | 0.05 € |
| Spread % | 0.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
